Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma

Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving drugs in different combinations may kill more cancer cells. It is not yet know which treatment regimen is more effective in treating Hodgkin lymphoma.

PURPOSE: This phase III trial is studying three different therapy regimens to compare how well they work in treating patients with previously untreated Hodgkin lymphoma.

Conditions

• Lymphoma

Interventions

BIOLOGICAL

bleomycin sulfate

Given IV

DRUG

ABVD regimen

Given IV

DRUG

carmustine

Given IV

DRUG

cisplatin

Given IV

DRUG

cytarabine

Given IV

DRUG

dacarbazine

Given IV

DRUG

dexamethasone

Given orally

DRUG

doxorubicin hydrochloride

Given IV

DRUG

etoposide

Given IV

DRUG

gemcitabine hydrochloride

Given IV

DRUG

ifosfamide

Given IV

DRUG

melphalan

Given IV

DRUG

methylprednisolone

Given IV

DRUG

mitoguazone

Given IV

DRUG

vincristine sulfate

Given IV

DRUG

vindesine

Given IV

DRUG

vinorelbine tartrate

Given IV

PROCEDURE

allogeneic hematopoietic stem cell transplantation

Patients undergo allogeneic stem cell transplantation

PROCEDURE

autologous hematopoietic stem cell transplantation

Patients undergo autologous stem cell transplantation

Sponsors & Collaborators

• French Innovative Leukemia Organisation

  lead OTHER

Principal Investigators

• Delphine Senecal · French Innovative Leukemia Organization

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Max Age

65 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2008-05-31

Primary Completion

2016-03-31

Completion

2016-03-31

Countries

• France

Study Locations